Cover Image
市場調查報告書

中國的心臟疾病治療藥市場的相關調查

Research on China Cardiovascular Drugs Industry, 2014-2018

出版商 Huidian Research 商品編碼 305401
出版日期 內容資訊 英文 85 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的心臟疾病治療藥市場的相關調查 Research on China Cardiovascular Drugs Industry, 2014-2018
出版日期: 2014年05月12日 內容資訊: 英文 85 Pages
簡介

在人口的高齡化,且患者殘餘生涯中需要藥物治療的慢性疾病的罹患率增加之下,中國的心臟疾病治療藥的市場有擴大趨勢。2013年,心臟疾病治療藥的市場達178億人民幣的規模。現在心臟疾病的罹患率在全部疾病中相對地高,也是治療困難的病。Huidian Research預測,2014年的中國的心臟疾病治療藥的銷售額推定達到約220億人民幣,2018年增加到450億人民幣。

本報告提供中國的心臟疾病治療藥市場相關研究、市場發展環境及競爭分析彙整、主要的心臟疾病治療藥的市場分析,以及主要企業簡介。

第1章 中國的心臟疾病治療藥產業概要

  • 中國的心臟疾病的患病情形
    • 心臟疾病定義
    • 心臟疾病患者數與死亡情形
    • 心臟疾病帶來的危險
  • 心臟疾病治療藥產業定義

第2章 中國的心臟疾病治療藥產業的發展環境

  • 中國的經濟發展環境
  • 影響產業發展的政策環境

第3章 醫藥品產業的發展情形

  • 主要經濟指標的實際成果
  • 主要的影響要素
  • 第12次5年計劃的主要配合措施的進展度
  • 2014年的情形預測

第4章 心臟疾病治療藥市場現狀

  • 國際心臟疾病治療藥市場發展情形
  • 中國的心臟疾病治療藥市場發展情形
  • 中國的競爭情形

第5章 中國的心臟疾病化學藥品的競爭分析

  • 心臟疾病化學藥品的市場簡介
  • 心臟疾病用藥物的市場分析
    • Alprostadil
    • 肌酸磷酸
    • 複合輔酶
  • 末稍血管擴張用藥物的市場分析
    • Cinepazide
    • Fasudil
    • Ligustrazine
  • Renin-angiotensin系用藥物的市場分析
    • Valsartan
    • Irbesartan
    • Losartan
    • Telmisartan
    • Benazepril
  • 鈣離子阻斷劑(CCB)的市場分析
    • Amlodipine
    • Nifedipine
    • Felodipine
    • Levamlodipine
    • Nimodipine
  • 抗脂肪血藥的市場分析
    • Atorvastatin Calcium
    • Simvastatin
    • Pravastatin
  • 乙型阻斷劑的市場分析
    • Bisoprolol
    • Metoprolol
    • Carvedilol
    • Esmolol
  • 抗高血壓藥的市場分析
  • 利尿劑的市場分析
    • Torasemide
    • Indapamide

第6章 心臟血管系統用中國專利藥物的競爭分析

  • 心臟血管疾病用中國專利藥物的市場簡介
  • 競爭情形
  • 9大城市醫院的心臟血管疾病用中國專利藥物
  • 主要的心臟血管疾病用中國專利藥物
    • Ginkgo注射
    • Danhong注射
    • Xueshuantong注射
    • Sanqi Panax Notoginseng注射
    • Cerecarton膠囊

第7章 心臟疾病治療藥產業上主要企業

  • 國際領導品牌與中國的投資
    • Pfizer
    • Novartis
    • Merck & Co., Inc.
    • Sanofi
    • Roche Holding Ltd.
  • 中國的心臟疾病治療藥的主要企業
    • Beijing SL PHARM
    • SALUBRIS
    • TASLY Pharm.
    • Taiantang Group
    • Guizhou Yibai Pharmaceutical Co., Ltd.
目錄

Research on China Cardiovascular Drugs Industry, 2014-2018 primarily carries on analyses on cardiovascular drugs market in the following aspects: market scale, the scale of segment markets, current competition status and business performance of major drug manufacturers; meanwhile it makes predictions about prospective market so as to help investors know this industry well and provide decision-making references for them.

With the aged tendency of population in China and the increasing morbidity of chronic diseases which have to be treated with medicines for the rest of patients' life, market scale of cardiovascular drugs is expanding. This trend has been reflected in recent years. While in the next few years, with the reform of medical insurance in China and the continuous standardization of pharmaceutical market as well as the unique curative effect of Chinese patent medicines, Chinese patents medicines for cardiovascular diseases will enjoy a promising development prospect.

In 2013 market scale of cardiovascular drugs has reached CNY 17.8 billion in China. At present cardiovascular diseases have a relatively higher morbidity rate among all diseases and also is a kind of disease that is hard to be cured. Along with the changes of people's life-styles, the difficulties in curing cardiovascular diseases are becoming more prominent. The compound annual growth rate of cardiovascular diseases is 21.6%, and the prevalence rate of cardiovascular diseases will increase further because of the improvements on people's living standards, the changes of life styles and increasing aging population. The market will be expanded.

On the other hand, patients with cardiovascular diseases have stood at 290 million, and patients with chronic diseases who have received systematic treatment account for a small proportion. In the next ten years, there is a potential for the growth in cardiovascular diseases treatment field. It is predicted that the growth rate will maintain more than 20% from 2014 to 2018. Huidian Research estimates that the sales scale of cardiovascular drugs in China in 2014 will reach about CNY 22 billion, and the figure will be CNY 45 billion by 2018.

Table of Contents

1. Overview of China Cardiovascular Drugs Industry

  • 1.1. Prevalence Situation of Cardiovascular Diseases in China
    • 1.1.1. Definition of Cardiovascular Diseases
    • 1.1.2. Number of Cardiovascular Patients and Death Situation
    • 1.1.3. Hazards of Cardiovascular Diseases
  • 1.2. Definition of Cardiovascular Drugs Industry

2. Development Environment of China Cardiovascular Drugs Industry

  • 2.1. China's Economic Development Environment
  • 2.2. Policy Environment Influencing Industry Development

3. Development Status of Pharmaceuticals Industry

  • 3.1. Performance of Major Economic Indicator
  • 3.2. Main Influence Factors
  • 3.3. Key Task Progress of the 12th Five-Year Plan
  • 3.4. Situation Forecast in 2014

4. Current Situation of Cardiovascular Drugs Market

  • 4.1. Development Situation of International Cardiovascular Drugs Market
  • 4.2. Development Status of China Cardiovascular Drugs Market
  • 4.3. Competitive Landscape in China

5. Competitive Analysis of China Cardiovascular Chemical Drugs

  • 5.1. Market Profile of Cardiovascular Chemical Drugs
  • 5.2. Market Analysis of Medicines for Heart Disease
    • 5.2.1. Alprostadil
    • 5.2.2. Creatine Phosphate
    • 5.2.3. Complex Coenzyme
  • 5.3. Market Analysis of Medicines for Peripheral Vascular Expansion
    • 5.3.1. Cinepazide
    • 5.3.2. Fasudil
    • 5.3.3. Ligustrazine
  • 5.4. Market Analysis of Medicines for Renin-angiotensin System
    • 5.4.1. Valsartan
    • 5.4.2. Irbesartan
    • 5.4.3. Losartan
    • 5.4.4. Telmisartan
    • 5.4.5. Benazepril
  • 5.5. Market Analysis of Calcium Channel Blockers (CCB)
    • 5.5.1. Amlodipine
    • 5.5.2. Nifedipine
    • 5.5.3. Felodipine
    • 5.5.4. Levamlodipine
    • 5.5.5. Nimodipine
  • 5.6. Market Analysis of Antilipemic Agents
    • 5.6.1. Atorvastatin Calcium
    • 5.6.2. Simvastatin
    • 5.6.3. Pravastatin
  • 5.7. Market Analysis ofβ-Blocking Agents
    • 5.7.1. Bisoprolol
    • 5.7.2. Metoprolol
    • 5.7.3. Carvedilol
    • 5.7.4. Esmolol
  • 5.8. Market Analysis of Antihypertensive Drugs
  • 5.9. Market Analysis of Diuretics
    • 5.9.1. Torasemide
    • 5.9.2. Indapamide

6. Competitive Analysis of Chinese Patent Medicines for Cardiovascular System

  • 6.1. Market Profile of Chinese Patent Medicines for Cardiovascular Diseases
  • 6.2. Competitive Landscape
  • 6.3. Chinese Patent Medicines for Cardiovascular Diseases in Hospitals of Nine Large Cities
  • 6.4. Main Chinese Patent Medicines for Cardiovascular Diseases
    • 6.4.1. Ginkgo Injection
    • 6.4.2. Danhong Injection
    • 6.4.3. Xueshuantong Injection
    • 6.4.4. Sanqi Panax Notoginseng Injection
    • 6.4.5. Cerecarton Capsules

7. Leading Enterprises of Cardiovascular Drugs Industry

  • 7.1. International Leading Brands and Their Investments in China
    • 7.1.1. Pfizer
    • 7.1.2. Novartis
    • 7.1.3. Merck & Co., Inc.
    • 7.1.4. Sanofi
    • 7.1.5. Roche Holding Ltd.
  • 7.2. Leading Enterprises of Cardiovascular Medicines in China
    • 7.2.1. Beijing SL PHARM
    • 7.2.2. SALUBRIS
    • 7.2.3. TASLY Pharm.
    • 7.2.4. Taiantang Group
    • 7.2.5. Guizhou Yibai Pharmaceutical Co., Ltd.
Back to Top